NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Rheumatoid Arthritis

Interventions: Tocilizumab, Glucocorticoid Agent

Countries: Belgium

This prospective, multicenter, observational study will evaluate the use of concomitant glucocorticoid therapy in adults with rheumatoid arthritis (RA) being treated with tocilizumab in daily clinical practice. Participants will be observed for up to 52 weeks after starting treatment with tocilizumab. All visits and assessments will be performed as per routine clinical practice, with no study-specific visits or interventions.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of moderate to severe RA, defined as DAS28 greater than or equal to 3.7
* Naive to tocilizumab, or received tocilizumab within 8 weeks prior to enrollment
* Physician has made decision to commence IV or SC tocilizumab in accordance with label and reimbursement criteria
* Treated with glucocorticoids for RA when starting tocilizumab treatment

Exclusion Criteria:

* Treatment with any investigational agent within 4 weeks or 5 half-lives before tocilizumab
* Continuous or regular treatment with oral corticosteroids for any indication other than RA

Locations (22)

Aalst, Belgium
Aalst, Belgium
Amel, Belgium
Bonheiden, Belgium
Bruges, Belgium
Brussels, Belgium
Brussels, Belgium
Céroux-Mousty, Belgium
Edegem, Belgium
Forchies-la-Marche, Belgium
Genk, Belgium
Genk, Belgium
Ghent, Belgium
Gilly (Charleroi), Belgium
Lier, Belgium
Liège, Belgium
Liège, Belgium
Mechelen, Belgium
Ostend, Belgium
Sijsele, Belgium
Turnhout, Belgium
Westmalle, Belgium